REGENXBIO Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- REGENXBIO Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $51.00K, a 34.62% decline year-over-year.
- REGENXBIO Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $118.00K, a 21.33% decline year-over-year.
- REGENXBIO Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $90.00K, a 136.84% increase year-over-year.
- REGENXBIO Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- REGENXBIO Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $318.00K, a 78.97% decline from fiscal 2024.
- REGENXBIO Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $1.51M, a 0.59% decline from fiscal 2023.
- REGENXBIO Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $1.52M, a 45.76% decline from fiscal 2022.
- REGENXBIO Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $2.80M, a 34.47% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $51.00K 10-Q · filed 2026-08-06 | $259.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $118.00K 10-Q · filed 2026-05-14 | $286.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $318.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $266.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $78.00K 10-Q · filed 2026-08-06 | $664.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $150.00K 10-Q · filed 2026-05-14 | $778.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.51M 10-K · filed 2026-03-05 |
| 2024-09-30 | $398.00K 10-Q · filed 2025-11-06 | $1.68M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $192.00K 10-Q · filed 2025-08-07 | $1.38M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $884.00K 10-Q · filed 2025-05-12 | $1.93M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $209.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.52M 10-K · filed 2025-03-13 |
| 2023-09-30 | $92.00K 10-Q · filed 2024-11-06 | $1.35M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $749.00K 10-Q · filed 2024-08-01 | $2.18M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $471.00K 10-Q · filed 2024-05-08 | $2.94M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $2.80M 10-K · filed 2025-03-13 |
| 2022-09-30 | $917.00K 10-Q · filed 2023-11-08 | $3.74M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $1.51M 10-Q · filed 2023-08-02 | $4.56M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $337.00K 10-Q · filed 2023-05-03 | $3.32M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $983.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $4.28M 10-K · filed 2024-02-27 |
| 2021-09-30 | $1.73M 10-Q · filed 2022-11-03 | $4.67M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $275.00K 10-Q · filed 2022-08-03 | $3.21M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $1.29M 10-Q · filed 2022-05-04 | $4.76M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $5.62M 10-K · filed 2023-02-28 |
| 2020-09-30 | $268.00K 10-Q · filed 2021-11-02 | $5.80M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $1.82M 10-Q · filed 2021-08-09 | $5.91M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $2.15M 10-Q · filed 2021-05-05 | $5.45M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $7.06M 10-K · filed 2022-03-01 |
| 2019-09-30 | $384.00K 10-Q · filed 2020-11-04 | $10.96M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $1.37M 10-Q · filed 2020-08-06 | $12.63M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $3.76M 10-Q · filed 2020-05-07 | $14.44M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $5.45M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $14.50M 10-K · filed 2021-03-01 |
| 2018-09-30 | $2.05M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $3.17M 10-Q · filed 2019-08-07 | |
| 2018-03-31 | $3.82M 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $2.49M 10-K · filed 2020-02-26 | |
| 2016-12-31 | $179.00K 10-K · filed 2019-02-27 | |
| 2015-12-31 | $107.00K 10-K · filed 2018-03-06 | |
| 2014-12-31 | $1.00K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |